Loading...

RAPT RAPT THERAPEUTICS INC Company Mergers 8-K Filing

RPT

RPT

RAPT THERAPEUTICS INC

(RAPT)

2024 8-K

Show Summary

Show Summary

- Delisting due to Non-Com...

Financial Statements

Financial Results

Investor Presentation

License Agreement

License Agreement

Stock Option Repricing

Financial Results

Earnings Reports

Workforce Reduction

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

FDA Clinical Hold

FDA Clinical Hold on Clinic...

Financial Results Announcement

Clinical Data Announcement

Sales Agreement

Earnings Reports

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Filing of Investor Presenta...

External Links:

RAPT Therapeutics entered into a License Agreement with Shanghai Jemincare for exclusive rights to develop and commercialize an anti-IgE monoclonal antibody, with an upfront payment of $35 million and potential milestone payments up to $672.5 million

AI Assistant

RAPT THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.